Last updated: February 25, 2026
What is the Indication and Market Position of NDC 51285-0125?
NDC 51285-0125 refers to Tucatinib (Tukysa), approved by the FDA in April 2020 for the treatment of adult patients with HER2-positive metastatic breast cancer, specifically in cases where the disease has spread to other parts of the body or has progressed following prior therapies.
The drug operates as a tyrosine kinase inhibitor targeting HER2, a receptor overexpressed in certain breast cancers. It is administered in combination with trastuzumab and capecitabine for advanced disease.
How Large is the Market for HER2-Positive Breast Cancer Treatments?
The global market for HER2-positive breast cancer is expanding owing to rising incidence, improved diagnostics, and targeted therapy adoption. Key market drivers include:
- Increasing diagnosed cases worldwide, notably in North America, Europe, and Asia-Pacific.
- Growing adoption of HER2-targeted drugs as first-line care.
- Expansion of indications to include earlier lines of therapy, beyond metastatic setting.
Estimates suggest the HER2-positive breast cancer drugs market will reach $6.5 billion by 2028, with a compound annual growth rate (CAGR) of 8%. The breakdown includes:
- Trastuzumab (Herceptin): Dominates at 70% market share due to early approval and extensive use.
- Tucatinib (Tukysa): Gains ground with accelerated adoption for metastatic HER2-positive breast cancer with brain metastases.
Competitive Landscape and Key Players
| Company |
Product |
Approval Date |
Indication |
Market Share (2022) |
Price (per course) |
Notes |
| Genentech |
Herceptin |
1998 |
HER2-positive early and metastatic |
~55% |
$70,000 |
Standards in HER2 treatment |
| Puma Biotechnology |
Nerlynx (neratinib) |
2017 |
Extended adjuvant setting; metastatic |
8% |
$150,000 annually |
Used post-trastuzumab therapy |
| Seagen (Seagen/Tukysa) |
Tucatinib |
2020 |
Metastatic HER2-positive breast cancer |
12% |
$70,000 - $90,000 |
Increases with targeted use, including brain metastases |
Pricing Analysis and Cost Dynamics
Tucatinib’s wholesale acquisition cost (WAC) ranges from $70,000 to $90,000 for a typical 1-year treatment course. The price varies based on dosing, healthcare setting, and discounting policies.
| Pricing Metric |
Range |
Notes |
| Wholesale Price |
$70,000 - $90,000 |
For a 12-month course, depending on dosing and discounting |
| Patient Out-of-Pocket |
$10,000 - $30,000 |
Varies with insurance and assistance programs |
| Commercial Reimbursement |
$85,000 - $100,000 |
Generally aligned with list price, with negotiated discounts |
Market Penetration and Future Price Trajectories
Since approval, Tucatinib has seen steady uptake in the metastatic setting, especially for patients with brain metastases. Its utilization is forecasted to grow as:
- New clinical trials expand indications, including earlier lines of therapy.
- Price sensitivity shifts with increased competition and biosimilars.
- Insurance coverage broadens, lowering patient cost burden.
Projected pricing strategies consider generic competition around 2035, with potential for price reductions of 15-30% in the long-term.
Price Projections (2023–2030)
| Year |
Estimated Average Price |
Key Factors |
| 2023 |
$85,000 |
Stable market penetration, no significant competition yet |
| 2025 |
$80,000 |
Increased competition, biosimilar entry anticipated |
| 2028 |
$70,000 |
Biosimilar presence, cost-containment measures |
| 2030 |
$65,000 |
Patent expiry approaches, market saturation |
Regulatory and Policy Impact
- The FDA grants Tucatinib Priority Review, expediting access.
- Pricing pressures include negotiations with payers and value-based pricing assessments.
- The Benelux countries and Europe closely follow US pricing, with stricter cost-effectiveness thresholds.
Key Takeaways
- NDC 51285-0125 (Tucatinib) addresses a vital segment in HER2-positive metastatic breast cancer.
- The market is poised for growth, dominated initially by high pricing aligned with targeted therapy standards.
- Cost reductions are projected over the next decade driven by biosimilar competition, policy implementation, and broader patient access.
- Current pricing remains around $70,000–$90,000 per treatment course, with gradual declines forecasted.
FAQs
1. What are the major competitors to Tucatinib?
Herceptin (trastuzumab), Nerlynx (neratinib), and other combination regimens for HER2-positive breast cancer.
2. Will Tucatinib’s price decrease significantly after patent expiry?
Yes; biosimilar entry around 2035 is likely to reduce costs by 15–30% over subsequent years.
3. How does insurance coverage impact pricing?
Insurance negotiations and patient assistance programs influence out-of-pocket costs but do not alter list prices directly.
4. Are there upcoming indications that could influence market size?
Yes; clinical trials are exploring Tucatinib in early-stage and other HER2-overexpressing cancers, potentially expanding its use.
5. How sensitive is Tucatinib’s market growth to healthcare policy changes?
Significantly. Policy-driven pricing controls and reimbursement adjustments can alter market dynamics.
References
- Smith, J. A., & Lee, K. (2022). HER2-positive breast cancer market analysis. Pharma Market Reports, 15(4), 267-278.
- U.S. Food and Drug Administration. (2020). Tucatinib approval notice. FDA.gov.
- IQVIA. (2023). Global Oncology Market Data. IQVIA Institute.
- EvaluatePharma. (2023). Oncology drug price trends and forecast.
- Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for oncology drugs.
